These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

206 related articles for article (PubMed ID: 23159581)

  • 1. Plasmacytoid urothelial carcinoma, a chemosensitive cancer with poor prognosis, and peritoneal carcinomatosis.
    Dayyani F; Czerniak BA; Sircar K; Munsell MF; Millikan RE; Dinney CP; Siefker-Radtke AO
    J Urol; 2013 May; 189(5):1656-61. PubMed ID: 23159581
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The Impact of Plasmacytoid Variant Histology on the Survival of Patients with Urothelial Carcinoma of Bladder after Radical Cystectomy.
    Li Q; Assel M; Benfante NE; Pietzak EJ; Herr HW; Donat M; Cha EK; Donahue TF; Bochner BH; Dalbagni G
    Eur Urol Focus; 2019 Jan; 5(1):104-108. PubMed ID: 28753857
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Pathological and Survival Outcomes Associated with Variant Histology Bladder Cancers Managed by Cystectomy with or without Neoadjuvant Chemotherapy.
    Hajiran A; Azizi M; Aydin AM; Zemp L; Peyton CC; Dhillon J; Nealon S; Reich RR; Cao B; Li R; Manley BJ; Sexton WJ; Gilbert SM
    J Urol; 2021 Jan; 205(1):100-108. PubMed ID: 32783489
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Outcome of patients with bladder cancer with pN+ disease after preoperative chemotherapy and radical cystectomy.
    Kassouf W; Agarwal PK; Grossman HB; Leibovici D; Munsell MF; Siefker-Radtke A; Pisters LL; Swanson DA; Dinney CP; Kamat AM
    Urology; 2009 Jan; 73(1):147-52. PubMed ID: 18848348
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Phase II clinical trial of neoadjuvant alternating doublet chemotherapy with ifosfamide/doxorubicin and etoposide/cisplatin in small-cell urothelial cancer.
    Siefker-Radtke AO; Kamat AM; Grossman HB; Williams DL; Qiao W; Thall PF; Dinney CP; Millikan RE
    J Clin Oncol; 2009 Jun; 27(16):2592-7. PubMed ID: 19414678
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Pathologic response in patients receiving neoadjuvant chemotherapy for muscle-invasive bladder cancer: Is therapeutic effect owing to chemotherapy or TURBT?
    Brant A; Kates M; Chappidi MR; Patel HD; Sopko NA; Netto GJ; Baras AS; Hahn NM; Pierorazio PM; Bivalacqua TJ
    Urol Oncol; 2017 Jan; 35(1):34.e17-34.e25. PubMed ID: 27639777
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Plasmacytoid urothelial carcinoma: response to chemotherapy and oncologic outcomes.
    Diamantopoulos LN; Khaki AR; Grivas P; Gore JL; Schade GR; Hsieh AC; Lee JK; Yezefski T; Yu EY; Schweizer MT; Cheng HH; Psutka SP; Lin DW; Tretiakova MS; Vakar-Lopez F; Montgomery RB; Wright JL
    Bladder Cancer; 2020; 6(1):71-81. PubMed ID: 34109262
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Plasmacytoid carcinoma of the bladder: a urothelial carcinoma variant with a predilection for intraperitoneal spread.
    Ricardo-Gonzalez RR; Nguyen M; Gokden N; Sangoi AR; Presti JC; McKenney JK
    J Urol; 2012 Mar; 187(3):852-5. PubMed ID: 22245324
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Site-Specific Differences of Eligibility for Adjuvant Immunotherapy Among Urothelial Carcinoma Patients Treated With Radical Surgery: Results From a Multicenter Cohort Study.
    Narita C; Urabe F; Fukuokaya W; Iwatani K; Imai Y; Yasue K; Mori K; Aikawa K; Yanagisawa T; Kimura S; Tashiro K; Tsuzuki S; Yamada Y; Yuen SKK; Teoh JY; Shimomura T; Yamada H; Furuta A; Miki J; Kimura T;
    Clin Genitourin Cancer; 2024 Jun; 22(3):102082. PubMed ID: 38641443
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The effect of concomitant carcinoma in situ on neoadjuvant chemotherapy for urothelial cell carcinoma of the bladder: inferior pathological outcomes but no effect on survival.
    Parker WP; Ho PL; Melquist JJ; Scott K; Holzbeierlein JM; Lopez-Corona E; Kamat AM; Lee EK
    J Urol; 2015 May; 193(5):1494-9. PubMed ID: 25451834
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Impact of adjuvant chemotherapy in patients with adverse features and variant histology at radical cystectomy for muscle-invasive carcinoma of the bladder: Does histologic subtype matter?
    Berg S; D'Andrea D; Vetterlein MW; Cole AP; Fletcher SA; Krimphove MJ; Marchese M; Lipsitz SR; Sonpavde G; Noldus J; Shariat SF; Kibel AS; Trinh QD; Mossanen M
    Cancer; 2019 May; 125(9):1449-1458. PubMed ID: 30620387
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Plasmacytoid urothelial carcinoma of the urinary bladder: a clinical pathological study and literature review.
    Wang Z; Lu T; Du L; Hu Z; Zhuang Q; Li Y; Wang CY; Zhu H; Ye Z
    Int J Clin Exp Pathol; 2012; 5(6):601-8. PubMed ID: 22949945
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Refining patient selection for neoadjuvant chemotherapy before radical cystectomy.
    Culp SH; Dickstein RJ; Grossman HB; Pretzsch SM; Porten S; Daneshmand S; Cai J; Groshen S; Siefker-Radtke A; Millikan RE; Czerniak B; Navai N; Wszolek MF; Kamat AM; Dinney CP
    J Urol; 2014 Jan; 191(1):40-7. PubMed ID: 23911605
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Preoperative chemotherapy for prostatic stromal invasive urothelial bladder cancer: comparison of oncological outcomes of male patients with cT4a disease undergoing radical cystectomy with or without preoperative chemotherapy.
    Chen J; Miranda G; Cai J; Daneshmand S; Djaladat H
    Scand J Urol; 2019; 53(2-3):123-128. PubMed ID: 31081431
    [No Abstract]   [Full Text] [Related]  

  • 15. Plasmacytoid urothelial carcinoma of the bladder: histological and clinical features of 5 cases.
    Fritsche HM; Burger M; Denzinger S; Legal W; Goebell PJ; Hartmann A
    J Urol; 2008 Nov; 180(5):1923-7. PubMed ID: 18801525
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Plasmacytoid variant urothelial bladder cancer: is it time to update the treatment paradigm?
    Kaimakliotis HZ; Monn MF; Cary KC; Pedrosa JA; Rice K; Masterson TA; Gardner TA; Hahn NM; Foster RS; Bihrle R; Cheng L; Koch MO
    Urol Oncol; 2014 Aug; 32(6):833-8. PubMed ID: 24954925
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Urothelial carcinoma in situ response to cisplatin-based neoadjuvant chemotherapy, or lack thereof: Impact on patient selection for organ preservation in muscle-invasive disease?
    Tachibana I; Bandali E; Calaway AC; Krishnan N; Cheng L; Adra N; Kaimakliotis HZ
    Urol Oncol; 2020 Nov; 38(11):850.e1-850.e7. PubMed ID: 32693973
    [TBL] [Abstract][Full Text] [Related]  

  • 18. "Real-world" outcomes and prognostic indicators among patients with high-risk muscle-invasive urothelial carcinoma.
    Drakaki A; Pantuck A; Mhatre SK; Dhillon PK; Davarpanah N; Degaonkar V; Surinach A; Chamie K; Grivas P
    Urol Oncol; 2021 Jan; 39(1):76.e15-76.e22. PubMed ID: 32778476
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Fibroblast Growth Factor Receptor 3 Alteration Status is Associated with Differential Sensitivity to Platinum-based Chemotherapy in Locally Advanced and Metastatic Urothelial Carcinoma.
    Teo MY; Mota JM; Whiting KA; Li HA; Funt SA; Lee CH; Solit DB; Al-Ahmadie H; Milowsky MI; Balar AV; Pietzak E; Dalbagni G; Bochner BH; Ostrovnaya I; Bajorin DF; Rosenberg JE; Iyer G
    Eur Urol; 2020 Dec; 78(6):907-915. PubMed ID: 32753285
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Neoadjuvant chemotherapy improves survival of patients with upper tract urothelial carcinoma.
    Porten S; Siefker-Radtke AO; Xiao L; Margulis V; Kamat AM; Wood CG; Jonasch E; Dinney CP; Matin SF
    Cancer; 2014 Jun; 120(12):1794-9. PubMed ID: 24633966
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.